Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Public ClinicalTrials.gov record NCT04662281. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1)
Study identification
- NCT ID
- NCT04662281
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Interventions
- LX9211 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 9, 2020
- Primary completion
- Nov 17, 2022
- Completion
- Dec 27, 2022
- Last update posted
- Feb 12, 2026
2020 – 2022
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lexicon Investigational Site | Scottsdale | Arizona | 85258 | — |
| Lexicon Investigational Site | Tucson | Arizona | 85741 | — |
| Lexicon Investigational Site | Greenbrae | California | 94904 | — |
| Lexicon Investigational Site | Brandon | Florida | 33511 | — |
| Lexicon Investigational Site (113) | Miami | Florida | 33032 | — |
| Lexicon Investigational Site | Miami | Florida | 33144 | — |
| Lexicon Investigational Site | Miami | Florida | 33174 | — |
| Lexicon Investigational Site | Ormond Beach | Florida | 32174 | — |
| Lexicon Investigational Site | Winter Park | Florida | 32789 | — |
| Lexicon Investigational Site (147) | Marietta | Georgia | 30060 | — |
| Lexicon Investigational Site | Flossmoor | Illinois | 60422 | — |
| Lexicon Investigational Site | Wauconda | Illinois | 60084 | — |
| Lexicon Investigational Site | Boston | Massachusetts | 02131 | — |
| Lexicon Investigational Site | Canton | Michigan | 48187 | — |
| Lexicon Investigational Site | Hazelwood | Missouri | 63042 | — |
| Lexicon Investigational Site | Albuquerque | New Mexico | 87102 | — |
| Lexicon Investigational Site (148) | Cary | North Carolina | 27518 | — |
| Lexicon Investigational Site | Jenkintown | Pennsylvania | 19046 | — |
| Lexicon Investigational Site | Baytown | Texas | 77521 | — |
| Lexicon Investigational Site | Victoria | Texas | 77901 | — |
| Lexicon Investigational Site | Salt Lake City | Utah | 84102 | — |
| Lexicon Investigational Site | Kenosha | Wisconsin | 53144 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04662281, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04662281 live on ClinicalTrials.gov.